MORRISVILLE, N.C., June 25, 2024 /PRNewswire/ -- Metabolon,
Inc., the global leader in providing metabolomics solutions
advancing a wide variety of life science research, diagnostic,
therapeutic development, and precision medicine applications, is
proud to announce the receipt of a prestigious grant from the
National Institutes of Health (NIH) to develop an innovative
product aimed at better monitoring and predicting the conversion of
preclinical asymptomatic type 1 diabetes (T1D) to clinical
symptomatic, insulin-dependent type 1 diabetes.
![](https://mma.prnewswire.com/media/1671125/Metabolon_Inc_Logo.jpg)
Over 3 million people in the United
States live with T1D. Today, the biomarkers that predict the
progression of preclinical T1D to clinical T1D lack specificity and
granularity. Despite advances in medical research, no single
FDA-approved test currently can monitor T1D progression beyond
simple disease staging. Metabolon's new initiative addresses this
unmet need by identifying metabolite biomarkers to improve
prediction and enable a more detailed understanding of disease
progression when evaluated alongside current clinical
indicators.
"Metabolon has a rich history of pioneering advancements in
metabolomics. We are dedicated to empowering pharmaceutical and
biotechnology companies, as well as academic and government
institutions, with comprehensive metabolic insights to drive better
health outcomes," said Ro Hastie, CEO of Metabolon. "With this NIH
grant, Metabolon is poised to extend its expertise in T1D, aiming
to enhance predictive capabilities and improve the lives of
millions affected by this condition."
If successful, Metabolon's research will enhance the specificity
and granularity of T1D progression prediction and pave the way for
more precise and personalized treatment strategies. By integrating
new metabolite biomarkers with existing clinical indicators,
Metabolon's efforts will significantly contribute to diabetes
research and patient care. For more information about Metabolon's
projects and services, please visit www.metabolon.com.
About Metabolon
Metabolon, Inc. is the global leader in metabolomics, with a
mission to deliver biochemical data and insights that expand and
accelerate the impact of life sciences research and complement
other 'omics' technologies. With more than 20 years, 10,000+
projects, 3,000+ publications, and ISO 9001:2015, CLIA, and CAP
certifications, Metabolon has developed industry-leading
scientific, technology, and bioinformatics techniques. Metabolon's
Global Discovery Panel is powered by the world's largest
proprietary metabolomics reference library. Metabolon's
industry-leading data and translational science expertise help
customers and partners address some of the most challenging and
pressing questions in the life sciences, accelerating research and
enhancing development success. The company offers scalable,
customizable multiomics solutions, including metabolomics and
lipidomics, that support customer needs from discovery through
clinical trials and product life-cycle management. For more
information, please visit www.metabolon.com and follow us on
LinkedIn and Twitter.
About Metabolomics
Metabolomics, the large-scale study
of all small molecules in a biological system, is the only 'omics
technology that provides a complete current-state functional
readout of a biological system. Metabolomics helps researchers see
beyond the genetic variation of individuals, capturing the combined
impact of genetic and external factors such as the effect of drugs,
diet, lifestyle, and the microbiome on human health. By measuring
thousands of discrete chemical signals that form biological
pathways in the body, metabolomics can reveal important biomarkers,
enabling a better understanding of a drug's mechanism of action,
pharmacodynamics, and safety profile, as well as individual
responses to therapy.
Logo -
https://mma.prnewswire.com/media/1671125/Metabolon_Inc_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/metabolon-receives-nih-grant-to-develop-advanced-monitoring-and-predictive-tools-for-type-1-diabetes-progression-302180642.html